AI assistant
GILEAD SCIENCES, INC. — Director's Dealing 2014
May 12, 2014
29828_dirs_2014-05-12_270d92a6-f74a-47ac-994e-00e8a697feea.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GILEAD SCIENCES INC (GILD)
CIK: 0000882095
Period of Report: 2014-05-08
Reporting Person: Carter Paul Rutherford (EVP Commercial Ops)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-05-08 | Common Stock | M | 16728 | $26.99 | Acquired | 45290 | Direct |
| 2014-05-08 | Common Stock | S | 16728 | $78.7986 | Disposed | 28562 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-05-08 | Non-Qualified Stock Option (right to buy) | $26.99 | M | 16728 | Disposed | 2018-07-30 | Common Stock (16728) | Direct |
Footnotes
F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
F2: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
F3: Sale prices reported for the transactions reported here range from $78.70 to $79.00. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.